SRNE News and Press, Sorrento Therapeutics Inc. From 10/06/22

SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Dr. Mike A. Royal, Chief Medical Officer, will participate in an upcoming Key Opinion Leader (KOL) Panel Discussion that will focus on the great unmet need ...

According to S&P Global Intelligence, the stock of the biotech firm focusing on cancer and pain medicines , Sorrento Therapeutics ( NASDAQ:SRNE ), fell 23.4% in September. SRNE stock ( NASDAQ:SRNE ) finished at $2.05 on August 31 before falling to a low of $1.52 on Sep...

Shares of Sorrento Therapeutics (NASDAQ: SRNE) , a biotech company that specializes in oncology and pain therapies, dropped 23.4% in September, according to data from S&P Global Intelligence . The stock closed at $2.05 on Aug. 31 then fell to a low of $1.52 on Sept. 29. The ...

Sorrento Therapeutics ( NASDAQ: SRNE ) announced on Friday a bridge loan agreement under which the company has borrowed ~$41.7M from B. Riley at 6% per annum interest. Per the agreement signed on Friday, SRNE has paid B. Riley 1% of the principal amount of the credit agree...

Scilex, a unit of Sorrento Therapeutics ( NASDAQ: SRNE ), said Thursday it pre-emptively paid off and eliminated all remaining senior secured notes in an aggregate principal amount of $67.7M for cash payment of ~$39.7M. Scilex will go public through a merger ...

PALO ALTO, Calif. and SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain,...

Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosed No limiting toxicities have been encountered during the trial to date. Patients are now being monitored for long-term safety and efficacy outcomes measures (6 and 12 months timepoints) Initial e...

SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced publication of peer-reviewed data detailing the discovery and preclinical profiling of antibodies from the Sorrento G-MAB™ library with neutralizing activity agai...

Sorrento Therapeutics ( NASDAQ: SRNE ) said that patients with rheumatoid arthritis who received Amgen's ( NASDAQ: AMGN ) Enbrel (etanercept) though the company's Sofusa Lymphatic Drug Delivery System showed improvement in disease activity, compared ...

Sorrento has now completed its first Phase 1b human proof of concept study where the first 7 out of 7 patients with an inadequate initial response on etanercept subcutaneous injections achieved significant improvements in disease activity when switched to Sofusa lymphatic delivery. Re...